CUMULATIVE INDEX 1993

Volume 11

February	CARDIAC ARRHYTHMIAS AND RELATED SYNDROMES, pages 1–198
May	EXERCISE TESTING AND CARDIAC REHABILITATION, pages 199–353
August	TRANSESOPHAGEAL ECHOCARDIOGRAPHY, pages 355–541
November	CONGENITAL HEART DISEASE IN ADOLESCENTS AND ADULTS, pages 543–738

Note: Page numbers of article titles are in **boldface** type

Ablative therapy of ventricular tachycardias, catheter ablation, 91–93
  accessory pathway ablation, 122, 143–144, 145
  activation mapping, 30
  of atrial tachycardias, 114, 118
  of atrioventricular nodal reentrant tachycardia, 170–173
  background, 91
  direct current (DC) ablation, 31, 91, 93
  efficacy and follow-up, 92–93
  electrocardiographic analysis of site of origin, 28–29
  localizing the site of origin, 27–30
  mapping and ablation techniques, 91–92
  mortality rates, 92, 93
  pace mapping, 30
  Percutaneous Cardiac Mapping and Ablation Registry, 91, 93
  radiofrequency energy, 31, 91, 122, 143, 171, 172
  risks and complications, 92
 chemical ablation, 31–32, 93
 surgical ablation, 85–91
  accessory pathway ablation, 140, 143
  activation mapping, 30, 86
  of atrial tachycardias, 114, 116, 118
  of atrioventricular nodal reentrant tachycardia, 169–170
  background and indications, 85–86
  catheter endocardial mapping, 86–87
  coronary revascularization for VT/VF, 90–91
  electrocardiographic analysis of site of origin, 28–29
  encircling endocardial ventriculotomy, 30–31, 86
  endocardial cryoablation, 31, 89
  implantable cardioverter-defibrillator vs., 103
  indications for map-guided surgery, 86
  intraoperative mapping, 87–88
  limitations, 31
  localizing the site of origin, 27–30
  mortality rate, 89, 90
  pace mapping, 30, 87
  postoperative and long-term follow-up, 89–90
  subendocardial resection, 86, 88–89
  transatrial balloon mapping, 88
  YAG laser photocoagulation, 93
Accessory pathways. See *Preexcitation syndromes.*
Accutane, cardiovascular malformations and, 560–561
Acquired long QT syndrome. See *Long QT syndrome, acquired.*
Acyanotic congenital heart disease, **603–616**
 atrial septal defect, 603–606
  anatomy and physiology of, 603–604
  clinical presentation of, 604
  as complication of mitral valvuloplasty, 422–423
  incidence of, 603
  medical and surgical management of, 604–605
  pregnancy and, 706
  transesophageal echocardiography of, 510–511
 atrioventricular canal defect, 609–612
  anatomy and physiology of, 609–610
  clinical presentation of, 610–611
  incidence of, 609
  medical and surgical management of, 611–612
 patent ductus arteriosus, 612–613
  anatomy and physiology of, 612
  clinical presentation of, 612
  incidence of, 612
  medical and surgical management of, 612–613
  patient survival in, 545, 549
  pregnancy and, 706
 pregnancy and, 705–706
 pulmonic stenosis, 613–615
  anatomy and physiology of, 613
  catheter-based dilation techniques and, 578–579
  clinical presentation of, 613–614
  incidence of, 613
  medical and surgical management of, 614–615
  patient survival in, 544, 546–547
 ventricular septal defect, 606–609
  anatomy and physiology of, 606
  clinical presentation of, 606–607
  endocarditis and, 598–599
  incidence of, 606
  medical and surgical management of, 607–609

Acyanotic congenital heart disease *(Continued)*
patient survival in, 549
pregnancy and, 706
Adenosine, in atrioventricular nodal reentrant tachycardia, 168
induction of atrial tachycardia, 112, 113
neurocardiogenic syncope and, 189
preexication syndromes and, 133, 144
Afterdepolarizations, in long QT syndrome, 44–45, 47, 48, 49
Aged. See *Elderly.*
Alcohol, cardiovascular malformations and, 560–561
Ambulatory monitoring, combined with other noninvasive methods, 60
for diagnosis of malignant tachycardia, 56–57
guiding of anti-arrhythmia drug therapy, 70
in monomorphic ventricular tachycardias, 25, 26
Americans with Disabilities Act of 1990, 713
Aminoglycosides, for endocarditis, 596, 597
Amiodarone, for acquired long QT syndrome, 50
Cardiac Arrest in Seattle Conventional Versus Amiodarone Drug Evaluation (CASCADE) Trial, 70, 71
as cause of polymorphic ventricular tachycardias, 47
empiric therapy for ventricular tachycardias, 69, 73–74, 77
for monomorphic ventricular tachycardias, 26–27
preexcitation syndromes and, 145
for prevention of atrioventricular nodal reentrant tachycardia, 168–169
Amoxicillin, for endocarditis, 596, 600
Ampicillin, for endocarditis, 596, 600
Anesthesia, in transesophageal echocardiography, 357–358
Aneurysm, atrial septal, systemic arterial emboli and, 453, 454
due to endocarditis, 590
right ventricular, after repair of tetralogy of Fallot, 647
Angina pectoris, delayed onset due to exercise training, 336, 339
exercise testing in patients with unstable angina, 235
Angioplasty. See *Coronary angioplasty.*
Angiotensin-converting enzyme inhibitors, exercise testing and, 245, 344
Anomalies of great arteries. See *Coarctation of aorta; Patent ductus arteriosus; Transposition of great arteries.*
Anti-arrhythmia agents. See also *specific agents.*
adverse effects of, 67
as cause of polymorphic ventricular tachycardias, 47
classification schemes for, 67, 68, 69
discontinuation before diagnosis of arrhythmias, 15
failure to reduce mortality, 73
in high risk patients, with previous lethal or potentially lethal tachyarrhythmias, 75–77
without previous lethal or potentially lethal tachyarrhythmias, 72–74
invasive vs. noninvasive selection of drugs, 70–71
methods for guiding therapy, 69–72
in monomorphic ventricular tachycardias, 25, 26
overview of, 66–67
preexcitation syndromes and, 145
for prevention of atrioventricular nodal reentrant tachycardia, 168–169
for subaortic stenosis, 623
Antibiotic prophylaxis, for endocarditis, 596–601
in transesophageal echocardiography, 358
Antibiotic therapy, for endocarditis, 595–597
Anticonvulsant drugs, cardiovascular malformations and, 560–561
Antidromic AV reentrant tachycardia, 123, 138–139, 144, 165
Aorta, coarctation of. See *Coarctation of aorta.*
transesophageal echocardiography of, scan planes for, 462
single, biplane, and multiplane views of, 384–385
Aortic atheroma, in systemic arterial emboli, 456–457
Aortic dissection vs. degenerative disease, transesophageal echocardiography of, **461–471**
accuracy of, 463
aortic insufficiency in, 469
classification of aortic dissection, 467
communicating and noncommunicating dissection in, 466–467
coronary artery involvement in, 468–469
diagnostic goals of, 469
differential diagnosis of, 462–465
echocardiograpic diagnosis of, 461–462
fluid extravasation in, 469–470
follow-up studies, 470–471
intimal tears in, 466
intramural hematoma and intramural hemorrhage in, 465–466
patient management in, 470
side branch involvement in, 467–468
true vs. false lumen in, 465, 466
Aortic regurgitation, 543, 647
Aortic valve disease, patient survival in, 543
after surgical therapy for, 547–548
Aortic valve insufficiency, exercise testing and, 242
with ventricular septal defect, 608
Aortic valve prosthesis, transesophageal echocardiography of, 433–435
limitations of, 434
normal range for Doppler measurement of, 434
Aortic valvular stenosis, 623–628. See also *Subaortic stenosis.*
anatomy and physiology of, 624–626
catheter-based dilation techniques and, 579–580
clinical manifestations of, 626–627
exercise testing and, 242
laboratory findings in, 627
management of, 627–628
pregnancy and, 706
prevalence of, 623–624
supravalvular, 628–630
Aortopulmonary shunts, patient survival after, 550–551
Arm ergometry, in exercise testing, 261–262
response to, relative to age and gender, 302
Arm-leg and static-dynamic exercise, **297–308**
dynamic arm exercise, 301–305
aerobic dance, 304–305
cross country skiing machines, 304
rationale for arm training, 303–304
rowers and combined arm-leg cycle ergometers, 304
swimming, 304
types of dynamic arm training, 304–305
dynamic leg exercise, 299–301
cycling, 300–301
jogging, 300
stairclimbing, 300
walking, 300
general concepts of dynamic and static exercise, 297–299
relative response to arm and leg exercise, 301
static (resistance) exercise, 262–263, 298, 305–307
Arrhythmias. See *Cardiac arrhythmias; specific types of arrhythmias.*
Aspirin, abnormal hemostasis and, 694
avoiding, in hyperuricemia, 697
Atheroma, aortic, in systemic arterial emboli, 456–457
Atherosclerosis, vs. aortic dissection, 462, 464–465

Atrial extrasystoles, in exercise testing, 250–251
Atrial fibrillation, accessory pathways and, 139–142
degeneration to ventricular fibrillation, 141–142
response to exercise testing, 225, 251
in subaortic stenosis, 623
Atrial malformations, transesophageal echocardiography of, atrial baffles, 514–515
atrial situs and anatomy, 514
Fontan operation and, 515–516, 517
systemic and pulmonary venous connections, 514
Atrial pacing, during echocardiography, 479
during transesophageal echocardiography, 526
Atrial septal defect, 603–606
anatomy and physiology of, 603–604
balloon-catheter septostomy for, 584
clinical presentation of, 604
as complication of mitral valvuloplasty, 422–423
incidence of, 603
medical and surgical management of, 604–605
pregnancy and, 706
secundum, patient survival in, 544–545
postsurgical, 548–549, 604–605
transcatheter closure techniques, 572–575
transesophageal echocardiography of, 510–511
Atrial septum, aneurysm of, and systemic arterial emboli, 453, 454
interatrial septal motion and pulmonary capillary wedge pressure, 483
in mitral stenosis, 413–414
Atrial tachycardia, in exercise testing, 251
Atrioventricular block. See under *Conduction abnormalities.*
Atrioventricular canal defect, 609–612
anatomy and physiology of, 609–610
clinical presentation of, 610–611
incidence of, 609
medical and surgical management of, 611–612
Atrioventricular junction, transesophageal echocardiography of, 516–518
Atrioventricular nodal reentrant tachycardia, **151–181**. See also *Supraventricular tachycardia.*
anatomic boundary of AVNRT circuit, 175–178
evidence for atrial participation in AVNRT, 177
lower turn around structure, 177
upper turn around structure, 175–177
antegrade atrioventricular nodal conduction properties, 154–155
association with other arrhythmias, 164–165
autonomic nervous system and, 166, 168
clinical manifestations of, 166
common atrioventricular nodal reentrant tachycardia, 152–154
differential diagnosis of, 163
dual vs. multiple pathways in, 173–174
electrocardiographic features of, 165–166
electrophysiologic characteristics of, 152–165
entrainment of, 161, 163
historical background of, 151–152
nonpharmacologic therapy for, 169–173
catheter ablation, 170–173
surgical ablation, 169–170
pharmacologic therapy for, 168–169
resetting phenomenon in, 158, 159–161
retrograde atrioventricular nodal conduction properties of, 155, 157, 158
uncommon atrioventricular nodal reentrant tachycardia, 163–164
Atrium, left. See *Left atrium.*
Atropine, for acquired long QT syndrome, 50
induction of atrioventricular nodal reentrant tachycardia, 166
and neurocardiogenic syncope, 189
Automatic border detection system, 391–393, 476

Balloon-catheter dilation. See *Catheter-based dilation techniques.*
Bepiridil, as cause of polymorphic ventricular tachycardias, 47
Beta-adrenergic blockaders, accessory pathways and, 122
in atrioventricular nodal reentrant tachycardia, 168, 169
as empiric therapy for ventricular tachycardias, 69, 76
exercise testing and, 245, 283, 344
in idiopathic long QT syndrome, 45, 46
induction and termination of atrioventricular nodal reentrant tachycardia, 168
neurocardiogenic syncope and, 189
preexication syndromes and, 133, 145
in subaortic stenosis, 622–623
Bicycle ergometry, advantages of, 202
calculating oxygen uptake, 202
rowers and combined arm-leg cycle ergometers, 304
treadmill exercise testing vs., 260–261
Biplane transesophageal echocardiography. See *Single, biplane, multiplane, and three-dimensional transesophageal echocardiography.*
Blood flow, in cardiopulmonary resuscitation, studies of mechanisms of, 531
theories of, 529–530
Blood pressure. See also *Hypertension.*
arterial blood pressure during exercise testing, 204
exertional hypotension, 220–221
response to exercise testing, 219–221, 247
Bradycardia, and neurocardiogenic syncope, 189
Bradykinin, and neurocardiogenic syncope, 189

Calcium channel blockers, accessory pathways and, 122
in atrioventricular nodal reentrant tachycardia, 168
exercise testing and, 245, 283, 344
preexcitation syndromes and, 145
for subaortic stenosis, 623
in ventricular tachycardias, 73, 77
Cardiac Arrest in Seattle Conventional Versus Amiodarone Drug Evaluation (CASCADE) Trial, 70, 71
Cardiac Arrhythmia Suppression Trial (CAST), Holter monitoring and selection of drug therapy, 25
implications for pharmacologic therapy, 66, 67, 73–74, 75
Cardiac arrhythmias. See also *Conduction abnormalities.*
atrioventricular nodal reentrant tachycardia, **151–181**
anatomic boundary: intranodal vs. extranodal location, 175–178
autonomic nervous system and, 166, 168
clinical manifestations of, 166
dual vs. multiple atrioventricular nodal pathways, 173–174
electrocardiographic features of, 165–166
electrophysiologic characteristics of, 152–165
history of, 151–152
nonpharmacologic therapy of, 169–173
pharmacologic therapy of, 168–169
classification and terminology of supraventricular tachycardia, **109–120**
comparative arrhythmias, in exercise testing, 274
detection of arrhythmias, in exercise testing, 272, 275

Cardiac arrhythmias *(Continued)*
drugs causing arrhythmias, 283
exercise-induced, 225, 236–237, 249
identification of high-risk patients, **55–63**
ambulatory monitoring, 56–57
combined noninvasive algorithm, 60–61
signal-averaged electrocardiography, 57–60
implantable cardioverter-defibrillator for, **97–108**
clinical needs and future direction, 104–109
compared with alternate approaches, 103
complications, 103–104
current status, 104
development of, 98–99
efficacy in terminating VT/VF, 99–103
impact on mortality, 103
monitoring, in long-term exercise programs, 282
monomorphic ventricular tachycardias, **21–37**
ablative therapy for, 27–32
drug therapy for, 25–27
mechanisms of, 21–22
natural history of, 22–25
pacemakers and cardioverter-defibrillators for, 32–33
substrates of, 22
neurocardiogenic syncope, **183–191**
history of, 183–184
neurocardiogenic mechanisms of, 185–189
patient evaluation in, 184–185
treatment of, 189–190
nonpharmacologic therapy for ventricular tachyarrhythmias, **85–96**
catheter ablation for, 91–93
surgical ablation for, 85–91
pharmacologic therapy for ventricular tachyarrhythmias, **65–83**
in high-risk patients, with previous lethal ventricular tachyarrhythmias, 75–77
without previous lethal ventricular tachyarrhythmias, 72–74
methods for guiding therapy, 69–72
overview of agents, 66–67
principles of successful management for, 67–69
polymorphic ventricular tachycardias, **39–54**
acquired long QT syndrome, 46–50
definitions, 39–40
idiopathic long QT syndrome, 40–46
ischemic heart disease and, 50–52
postsurgical, for transposition of great arteries, 654–655, 657–659
for tricuspid atresia with univentricular heart, 670–671
preexcitation syndromes, **121–149**
accessory pathways, arrhythmias associated with atrioventricular pathways, 134–142
associated with unidirectional conduction, 129, 131
atrioventricular, 121–129
with decremental conduction properties, 131, 133–134
treatment of, 143–145
in subaortic stenosis, 620
sudden cardiac death and, **1–9**
epidemiology and populations at risk, 6–7
substrate trigger interaction, 1–6
survivors of sudden cardiac death, **11–19**
complications of resuscitation, 11–12
diagnosis of arrhythmia, 14–17
diagnosis of heart disease, 12–14
management of, 17
in tetralogy of Fallot, 646
ventricular arrhythmias, 251, 282
Cardiac hemodynamics, transesophageal echocardiography and, **475–485**
left ventricular diastolic function, 479–483
interatrial septal motion and pulmonary capillary wedge pressure, 483
left ventricular filling and mitral inflow, 479–480
pulmonary venous flow and filling pressure, 480–483
left ventricular systolic function, 475–479
assessment of global left ventricular function, 475–477
atrial pacing and, 479
estimation of cardiac output, 478–479
evaluation of regional wall motion, 477–478
potential applications of, 484–485
severity of mitral regurgitation, assessment of, 483–484
Cardiac output, transesophageal echocardiographic estimation of, 478–479
Cardiac surgery, complications of, transesophageal echocardiography of, 495–497
Cardiac tamponade, as complication of mitral valvuloplasty, 421–422
Cardiac transplant donors, transesophageal echocardiography of, 500
Cardiac tumors, in systemic arterial emboli, 457–458
Cardiomyopathy, in exercise testing, 247
hypertrophic obstructive, anatomy and physiology of, 618–619
clinical manifestations of, 619–620
management of, 624–625
Cardiopulmonary resuscitation, cardiac pump theory vs. thoracic pump theory, 529–530
transesophageal echocardiography during, **529–535**
advantages of, 530–531
blood flow mechanism and, 531
new CPR methods and, 531–533
rapid diagnosis in, 533–534
transthoracic echocardiography and, 529–530
Cardiovascular risk factors. See *Risk factors.*
Cardioverter-defibrillator, implantable. See *Implantable cardioverter-defibrillator (ICD).*
CAST. See *Cardiac Arrhythmia Suppression Trial (CAST).*
Catecholamines, and neurocardiogenic syncope, 190
and preexcitation syndromes, 145
Catheter ablation of ventricular tachycardias. See *Ablative therapy of ventricular tachycardias.*
Catheter-based dilation techniques, 578–584. See also *Transcatheter closure techniques.*
for aortic coarctation, 583–584
for atrial septostomy, 584
choice of procedures, 585
for peripheral pulmonary arterial stenoses, 581–583
postoperative residual stenoses (conduitsaffles), 584
for valvular aortic stenosis, 579–580, 628
for valvular pulmonic stenosis, 578–579, 614
Catheterization and transesophagcal echocardiography, in congenital heart disease of adults, 508, 509, 683
Cefazolin, for endocarditis, 597
Ceftriaxone, for endocarditis, 596
Cerebrovascular ischemia. See also *Stroke.*
as cause of systemic arterial emboli, 447
Cesium, as cause of polymorphic ventricular tachycardias, 48
Chemical ablation of ventricular tachycardias, 31–32, 93
Chemicals, hazardous, cardiovascular malformations and, 561
Chest pain, transesophageal echocardiography of, 493–495

Cholinergic vasodilators, and neurocardiogenic syncope, 187
Chronotropic incompetence, in exercise testing, 221, 249–250
Classification of supraventricular tachycardias. See *Supraventricular tachycardia.*
Claudication. See *Peripheral arterial disease.*
Clindamycin, for endocarditis, 600
Clubbing, in hypertrophic osteoarthritis, 697
Coagulation disorders, cardiovascular malformations and, 560
Coagulation system, and exercise training, 344
Coarctation of aorta, 630–634
  anatomy and physiology of, 631–632
  catheter-based dilation techniques, 583–584
  clinical manifestations of, 632–633
  etiology of, 630–631
  laboratory findings in, 633
  management of, 633–634
  patient survival in, 543–544
    postsurgical, 549–550
  physical examination in, 633
  prevalence of, 630–631
Coma, following cardiac arrest, 12
Complications of congenital cyanotic heart disease, **689–699**
  erythrocytosis, 689–693
    classification of, 691–692
    Erythrophoresis Formula for calculation of whole blood removal, 683
    questionnaire for, 691
    regulation of red blood cell mass, 689–691
    therapeutic implications of, 692–693
    unusual sequelae of, 693
  hemostasis in, 694–695
  renal function and urate metabolism, 695–698
    acute gouty arthritis and, 696–698
    kidney function, 695
    urate metabolism, 695–696
Conduction abnormalities, atrial extrasystoles, 250–251
  atrial fibrillation, 251
  atrial tachycardia, 251
  complete atrioventricular block, 248
  exercise-induced, 225, 237
  fascicular block, 248
  first-degree atrioventricular block, 247–248
  intraventricular block, 249
  left bundle branch block, 225–226, 237, 248–249
  preexcitation syndrome, 248
  right bundle branch block, 226, 248
  second-degree atrioventricular block, 248
  sick sinus syndrome, 249–250
  ventricular arrhythmias, 251
  ventricular tachycardia, 251
Congenital heart disease in adults, acyanotic, **603–616**
    atrial septal defect, 603–606
    atrioventricular canal defect, 609–612
    patent ductus arteriosus, 612–613
    pulmonic stenosis, 613–615
    ventricular septal defect, 606–609
  aortic/mitral obstruction and coarctation of aorta, **617–641**
    coarctation of aorta, 630–634
    mitral valve obstruction, 634–638
    subaortic stenosis, 617–623
    supravalvular aortic stenosis, 628–630
    valvular aortic stenosis, 623–628
  Fontan procedure for tricuspid atresia and univentricular heart, **665–673**
    anatomy and, 665–669
    arrhythmias after, 670–671
    exercise capacity after, 670
    protein-losing enteropathy and, 671
    reoperation after, 670
    survival rates and criteria for, 669–670
infective endocarditis in, **589–601**
  clinical manifestations of, 593
  laboratory diagnosis of, 594–595
  microbiology of, 590–591
  pathogenesis of, 589–590
  predisposing factors for, 591–593
  prevention of, 597–601
  treatment of, 595–597
interventional catheter procedures for, **569–587**
  catheter-based dilation techniques, 578–584
interventional catheter procedures for, transcatheter closure techniques, 569–578
natural and postoperative history, **543–556**
  cardiopulmonary anastomoses for complex lesions, 554
  natural survival patterns, 543–546
  survival patterns after operation or catheterization, 546–554
pregnancy and contraception in, **701–709**
  acyanotic heart disease and, 705–706
  contraception and, 706–707
  counseling for, 702–703
  cyanotic heart disease and, 703–705
  physiologic changes during, 701–702
  prophylaxis for endocarditis and, 707
psychosocial issues in, **711–715**
  employability and insurability, 712–714
  patient knowledge of disease and, 711–712
  sexuality and childbearing, 712
pulmonary vascular obstructive disease, **675–687**
  laboratory investigation for, 682–683
  natural history and clinical course of, 676–677
  pathology and pathophysiology of, 677–680, 681, 682
  patient population of, 675–676
  physical examination for, 680–682
  therapy for, 683–684
systemic complications of cyanosis in, **689–699**
  erythrocytosis in, 689–693
  hemostasis and, 694–695
  renal function and urate metabolism in, 695–698
teratology, genetics, and risk recurrence in, **557–567**
  genetics, 562–563
  recurrence risks, 563–565
  teratology, 557–562
tetralogy of Fallot and pulmonary atresia/ventricular septal defect, **643–650**
  aortic regurgitation and, 647
  physical examination for, 644–645
  right ventricular aneurysm and, 647
  surgical therapy of, 645–647
    for pulmonary atresia, 647–649
training of physicians for, **717–720**
  body of knowledge required for, 718–719
  career decisions and, 720
  existing medical disciplines and, 717–718
  incorporation into existing pathways, 718
  subspecialty certification and, 719
  types of training experience required for, 719
transesophageal echocardiography of, **505–519**
  advantages and limitations of, 507
  atrial malformations, 514–516
    atrial baffles, 514–515
    atrial situs and anatomy, 514
    Fontan operation for, 515–516, 517

Congenital heart disease in adults *(Continued)*
systemic and pulmonary venous connections, 514
atrioventricular junction examination, 516–518
biplane enhancement of, 508
complex segmental malformations, 514–516
conotruncal anatomy, 518
coronary anomalies, 513
data acquisition and analysis, 506–507
esophageal view, 505–510
indications for, 506
interventional catheterization and, 508, 509
intraoperative evaluation, 507–508
objectives of, 508
left ventricular outflow tract lesions, 513
patient preparation, 506
right ventricular outflow tract lesions, 512–513
shunt lesions, 510–512
atrial septal defect, 510–511
systemic-to-pulmonary artery shunts, 512
ventricular septal defect, 511–512
transposition complexes, **651–664**
complete transposition of great arteries, 651–659
congenitally corrected transposition, 659–663
Congenital long QT syndrome, 40–42
Congestive heart failure. See also *Left ventricular dysfunction.*
in exercise programs, 283, 337, 339–340
exercise testing and, 237–238
severity of, based on exercise testing, 237
two-year survival in, 238
Conotruncal anatomy, transesophageal echocardiography of, 518
Contraception, in congenital heart disease, 706–707
Coronary angioplasty, exercise testing after, 235–236
percutaneous transluminal coronary angioplasty, 243–244
Coronary arteries, involvement in aortic dissection, 468–469
and sudden cardiac death, 3–4, 14
transesophageal echocardiography of, **521–526**
anomalies of, 513, 523
coronary vascular reserve and, 523–526
transthoracic echocardiography vs., **521–526**
Coronary revascularization, bypass surgery, 236, 243
coronary angioplasty, 235–236, 243–244
exercise testing after, 235–236
and polymorphic ventricular tachycardias, 90–91
reduced need for, 291–292
Critical care patients, transesophageal echocardiography of, **489–501**
cardiac surgery complications, 495–497
chest pain and complication of myocardial infarction, 493–495
complications of, 490
dyspnea and pulmonary edema, 491, 493
endocarditis and embolic sources, 497–500
hypotensive patients, 490–491
indications for, 489, 490
miscellaneous indications, 500
studies at U.C. San Francisco, 489–490
technical considerations, 501
Cyanotic congenital heart disease. See *Complications of congenital cyanotic heart disease.*
Cycle ergometry. See *Bicycle ergometry.*

Defibrillator, implantable. See *Implantable cardioverter-defibrillator (ICD).*
Dental procedures, bleeding from, 694
and prophylaxis for endocarditis, 599
Diabetes mellitus. See *Non-insulin-dependent diabetes mellitus.*
Dietary modification, psychobehavioral treatment for, 327–329
Digitalis, contraindication of, in subaortic stenosis, 622
effect on exercise testing, 244
Digoxin, for atrioventricular nodal reentrant tachycardia, 168
as cause of ST segment changes, 224, 283
and degeneration of atrial fibrillation to ventricular fibrillation, 142, 144, 145
Diltiazem, and atrioventricular nodal reentrant tachycardia, 168
Diphenylhydantoin, cardiovascular malformations and, 560–561
Disopyramide, as cause of polymorphic ventricular tachycardias, 47
and neurocardiogenic syncope, 189, 190
and preexcitation syndromes, 145
Dissection of the aorta. See *Aortic dissection vs. degenerative disease.*
Diuretics, as cause of arrhythmias, 283
as cause of ST segment changes, 224
effect on exercise testing, 245, 344
Drug therapy. See *Pharmacologic therapy.*
Drugs, cardiovascular malformations and, 560–561
Dynamic exercise. See *Arm-leg and static-dynamic exercise.*
Dyspnea, transesophageal echocardiography of, 491, 493

Early phase rehabilitative exercise, **267–275**
arrhythmias and, 272–275
education for, 267–268
exercise testing, 268–269
exercise training, 270
general principles of, 271–272
prognostic use of exercise testing, 269–270
six-level protocol for monitored phase II rehabilitation, 273
Ebstein's anomaly of tricuspid valve, survival after surgical procedure, 548
transcatheter closure techniques, 575
Edrophonium chloride, for induction of atrial tachycardia, 112
Efficacy studies in coronary rehabilitation, **333–347**
biological mechanisms of coronary heart disease prevention, 339
cardiovascular risk factors, 340–345
coagulation and fibrinolysis, 344
glucose intolerance, 342–343
hypertension, 343–344
lipoprotein levels, 340–342
smoking, 344–345
dropout rate in randomized clinical trials of rehabilitation, 345
morbidity and mortality, 334–340
Eisenmenger complex, 675
Eisenmenger syndrome. See also *Pulmonary vascular obstructive disease.*
with atrial septal defect, 604
with patent ductus arteriosus, 613
patient survival in, 545–546
pregnancy and, 609, 683–684, 703–704
pulmonary vascular obstructive disease vs., 675
with ventricular septal defect, 606, 609
Ejection fraction, abnormal, and risk of arrhythmia, 60
Elastase inhibitors, for pulmonary vascular obstructive disease, 680

Elderly, exercise testing in, 238
functional capacity of, 217
Electrocardiography during exercise testing, abnormal response, 222–224
computerization of, 205–206
in early phases of cardiac rehabilitation, 270
guidelines for monitoring exercise training, 273
lead systems, 205
modifiers of ST-segment response, 224–225
for monitoring exercise in early phase rehabilitation, 272
normal response, 221–222
prognostic impact of ST changes, 223–224
skin preparation, 204–205
ST segment changes, 222–225, 269
summary of angiographic studies, 205
T wave changes, 224
U wave, 224
Electrophysiologic characteristics, of atrioventricular nodal reentrant tachycardia, 152–165
antegrade atrioventricular nodal conduction properties, 154–155
association of AVNRT with other arrhythmias, 164–165
common atrioventricular nodal reentrant tachycardia, 152–154
differential diagnosis, 163
electrocardiographic features, 165–166
entrainment, 161, 163
resetting phenomenon, 158, 159–161
retrograde atrioventricular nodal conduction properties, 155, 157, 158
uncommon AVNRT, 163–164
of preexcitation syndromes, 123–129
antegrade conduction, 126
retrograde conduction, 126, 128–129
Electrophysiologic studies. See also *Ambulatory monitoring*.
diagnosis of arrhythmias, 14–17
invasive vs. noninvasive selection of drugs, 70–71
selection of drug therapy for ventricular tachycardias, 26, 75–76
signal-averaged electrocardiography, 57–60, 70
Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM), 25, 66, 71
Emboli, systemic. See *Systemic emboli, arterial*.
Embolization, from endocarditis, 590
from mitral stenosis, 638
vascular, transcatheter closure techniques, 577–578
Employability, of persons with congenital heart disease, 712–714
Encainide therapy, in CAST study, 73, 74
monomorphic ventricular tachycardias and, 26
Endocardial cushion defect. See *Atrioventricular canal defect*.
Endocarditis, cardiac imaging in, 437–438
in congenital heart disease, **589–601**
clinical manifestations of, 593
as complication of ventricular septal defect, 608
incidence in specific types of heart disease, 592
laboratory diagnosis of, 593–594
microbiology of, 590–591
pathogenesis of, 589–590
predisposing factors in, 591–593
prevention of, 596–601
cost/benefit and risk/benefit of, 598
impact of prophylaxis, 601
in pregnancy, 707
recommended antibiotic regimen, 598–600
in specific cardiac conditions, 598
in specific dental or surgical procedures, 599
treatment of, 595–597
for enterococcal infections, 595–596
for staphylococcal infections, 596
for *Streptococcus viridans*, 595–596
suggested antibiotic regiments for, 595, 596
transesophageal echocardiography in, 438–443
clinical implications of, 444
in critical care patients, 497–500
future developments in, 443–444
transthoracic echocardiography in, 438
Endorphins, and neurocardiogenic syncope, 189
Enterococcus species, in endocarditis, 590
antibiotic therapy for, 596, 597
Ephedrine, and neurocardiogenic syncope, 189, 190
Epidemiology of sudden cardiac death, 6–7. *See also* Sudden cardiac death.
Epinephrine, and neurocardiogenic syncope, 187
reversal of arrhythmia suppression by anti-arrhythmia agents, 76
Epistaxis, in congenital cyanotic heart disease, 694
Ergometry. See *Arm ergometry; Bicycle ergometry*.
Erythrocytosis, 689–693
classification of, 691–692
Erythrophoresis Formula for calculation of whole blood removal, 683
questionnaire for, 691
regulation of red blood cell mass, 689–691
therapeutic implications of, 692–693
unusual sequelae of, 693
Esmolol, and neurocardiogenic syncope, 190
Estrogen, effect on exercise testing, 245
ESVEM. See *Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)*.
Etilephrine, and neurocardiogenic syncope, 189
Exercise capacity, following surgery for tricuspid atresia with univentricular heart, 670
Exercise intensity, classification of intensity, 260
in early phases of cardiac rehabilitation, 271
in long-term exercise programs, 280, 281
prescribing, 255–259, 260
Exercise prescription, **253–266**
arm ergometry, 261–262
exercise intensity, 255–259, 260
graded exercise tests, 255–257, 261–264
guidelines for exercise prescription, 254
in long-term exercise programs, 280–282
rating of perceived exertion, 259–260
rehabilitation of heart disease, 253–255
resistance/weight training, 262–263
screening for coronary heart disease, 242–243
treadmill vs. cycle ergometer testing, 260–261
Exercise testing and cardiac rehabilitation, arm-leg and static-dynamic exercise, **297–308**
dynamic arm exercise, 301–305
dynamic leg exercise, 299–301
general concepts of dynamic and static exercise, 297–299
static (resistance) exercise, 305–307
early phase rehabilitative exercise, **267–275**
arrhythmias, 272–275
exercise testing, 268–269
exercise training, 270
general principles of, 271–272
patient education for, 267–268
prognostic use of exercise testing, 269–270
efficacy studies in coronary rehabilitation, **333–347**
cardiovascular risk factors, 340–345
morbidity and mortality, 334–340
exercise prescription, **253–266**

Exercise testing and cardiac rehabilitation *(Continued)*
arm ergometry, 261–262
exercise intensity, 255–259
rating of perceived exertion, 259–260
rehabilitation of heart disease, 253–255
resistance/weight training, 262–263
treadmill vs. cycle ergometer testing, 260–261
using graded exercise test, 255–257, 263–264
home-based and worksite-based exercise training, **285–295**
adherence to exercise program, 286
implementation of home-based training, 290–293
rationale for home-based training, 286–290
safety, 286, 291
worksite-based exercise, 293–294
interpretation of exercise tests, **215–227**
arrhythmias and conduction abnormalities, 225
blood pressure, 219–221
clinical responses, 215–216
electrocardiographic responses, 221–225
exercise-induced conduction disturbances, 225–226
functional capacity, 216–219
heart rate response, 221
long-term maintenance phase, **277–284**
drug effects, 283
exercise prescription, 280–282
general principles of exercise, 279–280, 281
medical evaluation for activity programs, 279
monitored exercise, 282
risks of physical activity, 277–279
special situations, 283–284
unmonitored exercise, 283
procedures and implementation, **199–213**
standard exercise testing, 199–207
ventilatory gas exchange analysis, 207–211
prognostic value of exercise testing, **229–240**
acute myocardial ischemic syndromes, 232–233, 234, 235
in asymptomatic subjects, 229–231
after coronary revascularization, 235–236
elderly patients, 238
before noncardiac surgery, 236
other heart abnormalities and diseases, 236–238
patients with unstable angina, 235
in symptomatic subjects, 231–232
testing after thrombolytic therapy, 233, 234
psychobehavioral treatment, **323–331**
dietary modification, 327–329
exercise training, 323–324
general psychological interventions, 326
smoking cessation, 326–327
type A behavior modification, 324–326
special populations, **309–321**
left ventricular dysfunction, 315–318
non-insulin-dependent diabetes mellitus, 313–315
peripheral arterial disease, 309–313
special situations, **241–252**
cardiomyopathies, 247
classification of cardiac function, 243
conduction abnormalities, 247–251
drug effects, 244–245
hypertension, 247
interpretation problems, 245–247
screening and evaluation before prescribing exercise, 242–243
surgical procedures, 243–244
valvular heart disease, 241–243
Exercise testing procedures and implementation, **199–213**
absolute and relative contraindications to, 203
arterial blood pressure in, 204
assessing maximal effort in, 206–207
computerization of, 205–206
electrocardiography and, 204–205
exercise modes, 201–201
heart rate in, 204
indications for stopping exercise, 206
patient preparation for, 203–204
personnel for exercise testing, 199–200
postexercise period, 207
protocols for, 200, 201
ramp testing, 200, 201
standard exercise testing, 199–207
ventilatory gas exchange analysis, 207–211
calculations for basic gas exchange data, 211
clinical applications, 207
hand signals for expressing pain, 210
measurement of oxygen uptake, 208–210
methodological considerations, 210–211
predicting oxygen uptake, 207–208

Fallot's tetralogy. See *Tetralogy of Fallot.*
Fibrillation. See *Ventricular tachycardia, with ventricular fibrillation.*
Fibrinolysis, and exercise effects, 344
Flecainide, in CAST study, 73, 74
and monomorphic ventricular tachycardias, 26
and preexcitation syndromes, 145
Fontan procedure, closure of fenestration via transcatheter technique, 577
patient survival after, 554
for repair of atrial malformations, 515–516, 517
for tricuspid atresia with univentricular heart, **665–671**
anatomy of tricuspid atresia, 665–669
arrhythmias following, 670–671
development of surgical procedure for, 667–669
exercise capacity following, 670
protein-losing enteropathy following, 671
reoperation for, 670
survival following, 669–670
Foramen ovale, patent. See *Patent foramen ovale.*
Functional capacity. See under *Oxygen uptake.*
Fungal endocarditis, 591, 597

Genetics of congenital cardiovascular malformations, 562–563. See also *Teratology of cardiovascular malformations.*
association of anomalies and, 562–563
chromosomal abnormalities in, 562
sibling risks of CHD, 563
single "cardiogenic" genes and, 563
syndromic associations and, 562
variability and heterogeneity in, 562
Gentamicin, for endocarditis, 596, 597, 600
Glenn procedure, patient survival after, 554
in tricuspid atresia with univentricular heart, 667
Glucose metabolism, effect of exercise programs on, 342–343
in patients with non-insulin-dependent diabetes mellitus, 314–315
Gouty arthritis, acute, in congenital cyanotic heart disease, 696–698
Graded exercise test. See *Exercise prescription.*
Gram-negative organisms, in endocarditis, 591, 597

Head-up tilt test, for neurocardiogenic syncope, 184–185, 186
Heart rate, chronotropic incompetence and, 221
in dynamic arm and leg exercise, 303
as indicator of exercise intensity, 255–259
as indicator of functional capacity, 217
measurement during exercise testing, 204
response to exercise testing, 221
variability of, for identification of high-risk survivors, 60
Heart transplantation, exercise training after, 284
Heart valve diseases, exercise testing for, aortic insufficiency, 242
aortic stenosis, 242
mitral prolapse, 242
mitral regurgitation, 242
mitral stenosis, 241–242
Heath-Edwards classification, of pulmonary vascular obstructive disease, 677–680
Hematoma, intramural, in aortic dissection, 465–466
Hemodynamics. See *Cardiac hemodynamics.*
Hemoptysis, in congenital cyanotic heart disease, 694
with mitral stenosis, 636
in pulmonary vascular obstructive disease, 684
Hemorrhage, in congenital cyanotic heart disease, 694–695
intramural, in aortic dissection, 465–466
Hemostasis, in congenital cyanotic heart disease, 694–695
High-risk patients. See *Risks of exercise training.*
Holter monitoring. See *Ambulatory monitoring.*
Home-based and worksite-based exercise training, **285–295**
adherence to exercise program, 286
implementation of home-based training, 290–293
MULTIFIT program, 290–293
rationale for home-based training, 286–290
safety, 286, 291
worksite-based exercise, 293–294
Hyperlipidemia, dietary modification for, 327–329
effect of exercise programs, 340–345
in individuals with coronary artery disease, 342
in individuals without cardiovascular disease, 340–342
Hypertension. See also *Pulmonary vascular obstructive disease.*
with coarctation of aorta, 632, 634
effect of exercise programs, 343–344
in exercise testing, 247
in pregnancy, 702
pulmonary, with mitral stenosis, 636
Hyperuricemia, in congenital cyanotic heart disease, 695–696
Hypotension, transesophageal echocardiography of, in critical care patients, 490–491
in intraoperative assessment of left ventricular function, 391
postsurgical, 496

Identification of high-risk survivors of sudden cardiac death. See *Sudden cardiac death.*
Idiopathic long QT syndrome. See *Long QT syndrome, idiopathic.*
Immune disorders, cardiovascular malformations and, 560
Implantable cardioverter-defibrillator (ICD), **97–108**
alternative therapies, 99, 100, 103
clinical needs and future direction, 104–107
complications of, 103–104
contraindications to, 100
cost of, 107
current status of, 104
development of, 98–99
discrimination between supraventricular and ventricular tachycardias, 105
drug therapy vs., 75
efficacy in ventricular tachycardias, 99–103
impact on cardiovascular mortality, 103
implantation during surgical ablation of ventricular tachycardias, 89–90
indications for, 97–98
as major and primary therapeutic option, 99
patient comfort and, 104–105
size of, 106–107
storage of information, 106
for subaortic stenosis, 623
survival rates with, 100–102
thoracotomy required for, 104
for ventricular tachycardias, 32–33
Implementation of exercise testing. See *Exercise testing procedures and implementation.*
Indications and technical considerations in transesophageal echocardiography, **355–359**
anesthesia and, 357–358
antibiotic prophylaxis in, 358
cleansing and storage of transesophageal probe, 357
complications in, 358–359
equipment, 356–357
indications and contraindications, 355–356
location of equipment, 357
personnel issues, 356
postprocedure instructions, 358
preliminary procedures, 357
probe insertion and examination, 358
Inotropic agents, in subaortic stenosis, 622
Insurability, of persons with congenital heart disease, 712–714
Intermittent claudication. See *Peripheral arterial disease.*
Interpretation of exercise tests, **215–227**
arrhythmias and conduction abnormalities, 225
blood pressure, 219–221
clinical responses, 215–216
electrocardiographic responses, 221–225
exercise-induced conduction disturbances, 225–226
functional capacity, 216–219
heart rate response, 221
Interventional catheter procedures. See *Catheter-based dilation techniques; Transcatheter closure techniques.*
Intimal tears, in aortic dissection, 466
Iodine–123-metaiodobenzylguanidine (MIBG), 42
Iron and iron deficiency, in erythrocytosis, 691–692
Ischemia, chronic ischemic heart disease, 231–232
effect of anti-arrhythmia agents, 74, 76, 77
global ischemia caused by cardiac arrest, 12
myocardial, acute myocardial ischemic syndromes, 232–233, 287
detecting, with transesophageal echocardiography, 393–396
silent, 230–231
and polymorphic ventricular tachycardias, 50–52
role in tachycardia, 56
Isoproterenol, for acquired long QT syndrome, 49–50
in atrioventricular nodal reentrant tachycardia, 168
effect on accessory pathways, 122
in idiopathic long QT syndrome, 45
and neurocardiogenic syncope, 185
reversal of arrhythmia suppression by anti-arrhythmia agents, 76

Isotretinoin, cardiovascular malformations and, 560–561

Junctional tachycardias, atrial vs. junctional tachycardias, 110–114
permanent junctional reciprocating tachycardia, 133–134

Kent bundle, 121, 133
Kidney function. See *Renal function and urate metabolism.*
Konno procedure, for subaortic stenosis, 622, 624–625

Late potentials, combined with other noninvasive diagnostic methods, 60
prognostic of ventricular tachycardias, 58–59
significance after myocardial infarction, 58
Left atrium, spontaneous echocontrast of, in mitral regurgitation, 406
systemic arterial emboli and, 451–453
thrombus of, as contraindication for mitral valvuloplasty, 411
as source of systemic arterial emboli, 449–451
transesophageal echocardiography of, in mitral regurgitation, 405–406
Left bundle branch block, 225–226, 237, 248–249. See also *Conduction abnormalities.*
Left ventricle, in mitral stenosis, 412
outflow tract malformations of, transesophageal echocardiography of, 513
Left ventricular dysfunction, 315–318
adverse effects of exercise training, 318
background of, 315–316
exercise training and, 291, 317–318
exercise training studies and, 316–317
pathophysiology of exercise and, 316
Left ventricular function, intraoperative transesophageal echocardiography of, **389–396**
global left ventricular function, 389–393
afterload, 391
automatic border detection, 391–393, 392
contractility, 391
preload, 389–391
segmental wall motion abnormalities, 393–396
regional ischemia, detection of, 393–396
transesophageal echocardiography of, diastolic function, 479–483
interatrial septal motion and pulmonary capillary wedge pressure, 483
left ventricular filling and mitral inflow, 479–480
pulmonary venous flow and filling pressure, 480–483
in mitral regurgitation, 406
systolic function, 475–479
atrial pacing and, 479
estimation of cardiac output, 478–479
global left ventricular systolic function, 475–477
regional wall motion in, 477–478
Leg exercise, dynamic. See *Arm-leg and static-dynamic exercise.*
Lidocaine, for acquired long QT syndrome, 50
and degeneration of atrial fibrillation to ventricular fibrillation, 142, 144
Lipid metabolism, in patients with non-insulin-dependent diabetes mellitus, 315
Lithium, cardiovascular malformations and, 560–561
Long QT syndrome, acquired, 46–50
clinical presentation of, 46–47
mechanism of, 47–49
therapy of, 49–50
idiopathic, 40–46
clinical presentation, 41–42
congenital, 40–42
diagnosis, 42–43
mechanisms, 43–45
treatment, 45–46
Long-term exercise programs, **277–284**
drug effects, 283, 344
exercise prescription, 280–282
general principles of exercise, 279–280, 281
guidelines for exercise, 281
medical evaluation for activity programs, 279
monitored exercise, 282
risks of physical activity, 277–279
social-learning model of learning health behaviors, 289–290
special situations, 283–284
unmonitored exercise, 283
Low-risk patients. See *Risks of exercise training.*
Lumen, true vs. false, in aortic dissection, 465

Magnesium, for acquired long QT syndrome, 50
in idiopathic long QT syndrome, 46
Mahaim fibers (right atriofascicular pathways), 121, 131, 133
Map guided ablative therapy. See *Ablative therapy of ventricular tachycardias.*
Maximum oxygen uptake. See *Oxygen uptake.*
Membranous subaortic stenosis, 619, 621–622
Iodine-123-metaiodobenzylguanidine (MIBG), 42
Mexiletine therapy, in monomorphic ventricular tachycardias, 26
Mitral regurgitation, and exercise testing, 242
mitral valvuloplasty and, complication of, 420
contraindication for, 411
transesophageal echocardiography of, **399–407**
assessing severity of, 483–484
color flow imaging in, 483–484
pulmonary venous flow as marker of, 484
color flow detection and grading of, 399–402
agitated flow in left atrium and, 401
color flow jet in pulmonary vein(s) and, 401
jet area as guide to severity of, 400
jet circling left atrium and, 401
jets in left atrial appendage and, 401
proximal acceleration signals and severity of, 401–402
size of jet and severity of, 402
wall-hugging jets and, 400–401
pulsed and continuous wave Doppler findings in, 402–407
abnormal mitral valve morphology and, 406–407
decreased left ventricular outflow volume and, 403–404
decreased transaortic flow velocity and, 403–404
exaggerated systolic expansion of left atrium and, 405
increased density of continuous wave Doppler jet and, 404
increased mitral inflow velocity and, 403
interatrial septal bulges and, 405–406
lack of spontaneous contrast in left atrium and, 406
left atrial dilation and, 405

left ventricular contractility and, 406
left ventricular enlargement and, 406
right ventricular enlargement and, 407
spontaneous contrast in aorta and, 406
systolic reversal in pulmonary venous flow and, 402–403
two-dimensional echocardiographic signs of, 405–407
V-wave cut-off sign of mitral regurgitation jet and, 404–405
Mitral valve, transesophageal echocardiography of, in endocarditis, 442–443
inflow velocity and, 479–480
Mitral valve prolapse, endocarditis and, 592–593, 598
exercise testing and, 242
Mitral valve prosthesis, transesophageal echocardiography of, 428–433
limitations in, 433
normal range for Doppler measurement of, 432
Mitral valve stenosis, 634–638
clinical manifestations of, 636–637
exercise testing and, 241–242
laboratory findings in, 637
management of, 637–638
physiology of, 635–636, 637
pregnancy and, 705, 706
prevalence and types of, 634–635
Mitral valvuloplasty, mitral regurgitation and, complication of, 420
contraindication for, 411
transesophageal echocardiographic guidance of, **409–423**
anatomy of mitral apparatus and, 410–411
balloon positioning and dilatation, guidance of, 416–417
baseline Doppler hemodynamics of, 412
complications in, 419–423
iatrogenic atrial septal defect, 422–423
mitral regurgitation, 420
serious complications, 420
systemic embolization, 421
tamponade, 421–422
immediate assessment of results, 417–419
left atrial thrombi and, 411
mitral regurgitation and, 411
patient selection, 410–414
special considerations in, atrial septal anatomy and, 413–414
left ventricular size, 412–414
mitral valve funnel in, 412–413
transseptal puncture, guidance of, 414–416
Moderate- to high-risk patients. See *Risks of exercise training*.
Monomorphic ventricular tachycardias. See under *Ventricular tachycardia*.
Moricizine, adverse effects of, 67
in CAST study, 73
as cause of polymorphic ventricular tachycardias, 47
in monomorphic ventricular tachycardias, 26
Mortality rates. See also *Sudden cardiac death; Survival of patients with congenital heart disease*.
annual mortality of patients with coronary disease, 230, 287
cumulative mortality in asymptomatic men, 230
decreased rates due to exercise training, 333, 334–340
patients with ischemic heart disease, 231–232
pooled results of randomized trials of cardiac rehabilitation, 337, 338, 345
Multicenter Unsustained Tachycardia Trial (MUSTT), 71, 74
Multifocal atrial tachycardia, 118
Multiplane transesophageal echocardiography. See *Single, biplane, multiplane, and three-dimensional transesophageal echocardiography*.
Mustard procedure, for transposition of great arteries, 653–657
Myocardial infarction, exercise training after anterior infarction, 284
non-Q wave myocardial infarction, 235
predictors of death or reinfarction, 234, 340
prognostic value of exercise testing, 232–233, 234
transesophageal echocardiography of, 493–495
Myocardial ischemia. See *Ischemia*.
Myocardium, in sudden cardiac death, 4

Nafcillin, for endocarditis, 597
Naloxone, and neurocardiogenic syncope, 189
National Rehabilitation Act of 1973, 713
Natural History of Congenital Heart Defects Study, 578, 579, 614, 712, 713–714
Neodymium:yttrium-aluminum-garnet (YAG) laser photocoagulation, for ablation of ventricular tachycardias, 93
Neurocardiogenic syncope, **183–191**
definition of, 183
head-up tilt test, 184–185, 186
history of, 183–184
neurocardiogenic mechanisms, 185–189
patient evaluation in, 184–185
related to atrioventricular nodal reentrant tachycardia, 166
treatment of, 189–190
Non-insulin-dependent diabetes mellitus, 313–315
background of, 313
exercise testing in, 313–315
special considerations for, 315
Nonparoxysmal sinus tachycardia, 115
Noonan syndrome, 613
Norepinephrine, and neurocardiogenic syncope, 187, 189

Occupational exposure to hazardous chemicals, cardiovascular malformations and, 561
Opioid peptides. See *Endorphins*.
Orthodromic AV reentrant tachycardia, 123, 134–138, 144–145, 165
Ouabain, effect on accessory pathways, 122–123
Oxacillin, for endocarditis, 597
Oxygen uptake, calculating, bicycle ergometry testing, 202
calculations for basic gas exchange data, 211
equation for oxygen uptake, 209
treadmill testing, 203
functional capacity, in cardiac disease, 217–219
classification, 216–217
heart rate, 217
maximum oxygen uptake as measure of functional capacity, 216–217, 268–269, 270
perceived work effort correlated to percent of maximum uptake, 217, 218
relationship with age and activity status, 217, 218
resting oxygen uptake values in healthy patients, 217
resting ventricular function and VO_2, 219
workload and treadmill time, 217
improvement after exercise, 278
as indicator of exercise intensity, 255, 298–299

Oxygen uptake *(Continued)*
measurement of, 208–210
prediction of, 207–208
relationship between predicted and measured oxygen uptake, 208
slopes in oxygen uptake vs. work rate, 202

Pacemakers, for acquired long QT syndrome, 49–50
antitachycardia, for ventricular tachycardias, 32–33
and neurocardiogenic syncope, 189
for subaortic stenosis, 623
after surgical repair for transposition of great arteries, 655, 658
Patent ductus arteriosus, 612–613
anatomy and physiology of, 612
clinical presentation of, 612
incidence of, 612
medical and surgical management of, 612–613
patient survival in, 545
postsurgical, 549
pregnancy and, 706
transcatheter closure techniques, 569–572
Patent foramen ovale, in systemic arterial emboli, 453–456
association with systemic emboli, 455–456
diagnosis of, 453, 455
transcatheter closure techniques, 575
Penicillin therapy, for endocarditis, 595–597, 600
Perceived exertion. See *Rating of perceived exertion.*
Percutaneous Cardiac Mapping and Ablation Registry, 91, 93
Percutaneous transluminal coronary angioplasty. See *Coronary angioplasty.*
Percutaneous transvenous balloon mitral valvuloplasty (PBMV). See *Mitral valvuloplasty.*
Peripheral arterial disease, 309–313
background of, 309
evaluation of exercise performance and, 311
exercise training methods and, 311–313
treatment of, 309–310
Peripheral pulmonary arterial stenoses, catheter-based dilation techniques for, 581–583
Pesticides, cardiovascular malformations and, 561
Pharmacologic therapy, in atrioventricular nodal reentrant tachycardia, 168–169
of endocarditis, in congenital heart disease, 595–597
in monomorphic ventricular tachycardias, 25–27
in preexcitation syndromes, 144–145
in ventricular tachycardias, **65–83**
classification schemes, 67, 68, 69
invasive vs. noninvasive selection of drugs, 70–71
methods for guiding therapy, 69–72
overview of anti-arrhythmic agents, 66–67
principles of successful management, 67–69
summary of drug use, 78
with previous lethal or potentially lethal tachycardias, 75–77
without previous lethal or potentially lethal tachycardias, 72–74
Phenylketonuria, and teratology of cardiovascular malformations, 560
Phlebotomy, for abnormal hemostasis, 694
for erythrocytosis, 692–693
Physician training. See *Training of physicians for care of adult congenital heart disease.*
Platelet-derived growth factor (PDGF), 698
Platelet production, from megakaryocytes, 697
Polycythemia. See *Erythrocytosis.*
Polymorphic ventricular tachycardias. See under *Ventricular tachycardia.*
Preexcitation syndromes, **121–149**
accessory pathways, 121–134
antegrade conduction, 126
atrioventricular pathways associated with preexcitation, 121–129
decremental (atrioventricular nodal-like) conduction properties, 131, 133–134
electrocardiographic and electrophysiologic characteristics, 123–129
identification of location, 129
Kent bundle, 121, 133
Mahaim fibers (right atriofascicular pathways), 121, 131, 133
permanent junctional reciprocating tachycardia, 133–134
retrograde conduction and, 126, 128–129
right atriofascicular pathway, 133
unidirectional conduction and, 129, 131
arrhythmias associated with accessory pathways, 134–142
antidromic atrioventricular reentrant tachycardia, 138–139
atrial fibrillation, 139–142
orthodromic atrioventricular reentrant tachycardia, 134–138
treatment of, 143–145
ablative therapy, 143–144
acute management, 144
in asymptomatic patients, 145
chronic pharmacologic therapy, 144–145
Pregnancy in congenital heart disease, **701–709**. See also *Teratology of cardiovascular malformations.*
acyanotic heart disease and, 705–706
contraception and, 706–707
counseling for, 702–703
cyanotic heart disease and, 703–705
Eisenmenger syndrome and, 609, 683–684, 703–704
maternal diabetes and, 560
mortality rate, in ventricular septal defect, 609
offspring risks, 563–564
physiologic changes in, 701–702
prophylaxis for endocarditis in, 707
psychosocial issues in, 712
Proarrhythmia, caused by anti-arrhythmia agents, 26, 27, 67
definition of, 27
possibility of, during catheter ablative therapy, 92
Procainamide, in atrioventricular nodal reentrant tachycardia, 168
as cause of polymorphic ventricular tachycardias, 47
in monomorphic ventricular tachycardias, 26
and preexcitation syndromes, 145
Prognostic value of exercise testing, **229–240**
in acute myocardial ischemic syndromes, 232–233, 234, 235
in asymptomatic subjects, 229–231
in cardiac arrhythmias, 236–237
in chronic ischemic heart disease, 231–232
in conduction abnormalities, 237
in congestive heart failure, 237–238
after coronary revascularization, 235–236
in early phases of cardiac rehabilitation, 269–270
in elderly patients, 238
mortality rates and, 230, 232
after non-Q wave myocardial infarction, 235
before noncardiac surgery, 236
in other heart abnormalities and diseases, 236–238
in patients with unstable angina, 235

as predictors of death or reinfarction, 234
prognostic value of treadmill score, 232
in silent myocardial ischemia, 230–231
survival rates and, 231, 235, 236, 238
in symptomatic subjects, 231–232
after thrombolytic therapy, 233, 234
Programmed stimulation, intraoperative mapping during surgical ablation of tachycardias, 87
for selection of drug therapy, in monomorphic ventricular tachycardias, 25–26
in patients with ventricular tachycardias, 75, 76
Propafenone, and preexcitation syndromes, 145
Propranolol, and neurocardiogenic syncope, 185
Prostaglandins, and neurocardiogenic syncope, 189
Prosthetic valves, transesophageal echocardiography of, **427–435**
aortic valve prosthesis, 433–435
approach to assessment, 428
mitral valve prosthesis, 428–433
postsurgical, 497
tricuspid valve prosthesis, 435
Protein-losing enteropathy, following surgery for tricuspid atresia with univentricular heart, 671
Protocols for exercise testing, common protocols, 200
oxygen cost per stage of exercise protocol, 201
phase II nonmonitored exercise training protocol, 274
ramp testing, 200, 201
six-level protocol for monitored phase II rehabilitation, 273
slopes in oxygen uptake vs. work rate, 202
Psychobehavioral treatment in cardiac rehabilitation, **323–331**
dietary modification, 327–329
exercise training, 289–290, 323–324
general psychological interventions, 326
smoking cessation, 326–327
social-learning model of learning health behaviors, 289–290
type A behavior modification, 324–326
Psychological benefits of exercise training, 285–286, 326
Psychosocial issues in congenital heart disease, **711–715**
employability and insurability, 712–714
patient knowledge of disease, 711–712
sexuality and childbearing, 712
Pulmonary arterial stenoses, peripheral, catheter-based dilation techniques for, 581–583
Pulmonary artery, estimating pressure of, with transesophageal echocardiography, 484–485
systemic-to-pulmonary artery shunts of, 512
Pulmonary atresia. See *Tetralogy of Fallot, with pulmonary atresia and ventricular septal defect.*
Pulmonary capillary wedge pressure, interatrial septal motion and, 483
after regional ischemia, 394
Pulmonary edema, transesophageal echocardiography of, 491, 493
Pulmonary valve, endocarditis of, transesophageal echocardiography of, 440
Pulmonary valvular stenosis, 613–615
anatomy and physiology of, 613
catheter-based dilation techniques and, 578–579
clinical presentation of, 613–614
incidence of, 613
medical and surgical management of, 614–615
patient survival in, 544
after surgical valvotomy, 546–547
Pulmonary vascular obstructive disease. See also *Eisenmenger syndrome.*
Eisenmenger syndrome vs., 675
laboratory investigation of, 682–683
natural history and clinical course of, 676–677
pathology and pathophysiology of, 677–680, 681, 682
grade A, 677
grade B, 677
grade C, 677
Heath-Edwards classification, 677–680
physical examination of, 680–682
prevalence of, 675–676
therapy of, 683–684
Pulmonary veins, transesophageal echocardiography of, single, biplane, and multiplane views of, left pulmonary veins, 382–383
right pulmonary veins, 383–384
systemic and pulmonary venous connection anomalies, 514
venous flow, in left ventricular diastolic function, 480–483
as marker of mitral regurgitation severity, 484
systolic reversal of, in mitral regurgitation, 402–403

Quinidine, as cause of polymorphic ventricular tachycardias, 47, 48
effect on exercise testing, 244–245
and preexcitation syndromes, 145

Radiography, for endocarditis, 594
Radionuclide imaging, for endocarditis, 595
Ramp testing, 200, 201
Rating of perceived exertion, as basis for exercise prescription, 259–260
Borg scale, 258, 268, 269
in early phases of cardiac rehabilitation, 271
relationship between heart rate and perceived exertion, 258
Regional wall motion. See *Segmental wall motion abnormalities.*
Rehabilitation. See *Exercise testing and cardiac rehabilitation.*
Renal function and urate metabolism, in congenital cyanotic heart disease, kidney function, 695
urate metabolism, 695–696
Resistance/weight training for cardiac rehabilitation, 262–263, 298, 305–306
Resuscitation complications, in survivors of sudden cardiac death, 11–12
Rheumatic heart disease, endocarditis in, 590
Rifampin, for endocarditis, 597
Right bundle branch block, 226, 248. See also *Conduction abnormalities.*
Right ventricle, transesophageal echocardiography of, in mitral regurgitation, 407
in outflow tract malformations, 512–513
Risk factors, exercise training and, coagulation and fibrinolysis, 344
glucose intolerance, 342–343
glucose metabolism, in non-insulin-dependent diabetes mellitus, 314–315
hypertension, 247, 343–344
smoking, 326–327, 344–345
hyperlipidemia, dietary modification programs, 327–329
lipid metabolism, in non-insulin-dependent diabetes mellitus, 315
lipoprotein and cholesterol levels, 340–342
for populations at risk for sudden cardiac death, 6–7

Risks of exercise training, in long-term exercise programs, 277–279
for low-risk patients, 271
screening process, 272
for moderate- to high-risk patients, 271
basic requirements for supervised programs, 272
screening process for high-risk patients, 271
risk of sudden death, 278, 286
Rubella, teratology and, 557

Secundum atrial septal defect. See *Atrial septal defect.*
Segmental wall motion abnormalities, analysis system for, 395
evaluation of, 477–478
after regional ischemia, 393–396
Septum. See *Atrial septal defect; Atrial septum; Ventricular septal defect.*
Shunt, aortopulmonary, patient survival after, 550–551
systemic-to-pulmonary artery, 512
Shunt abnormalities, transesophageal echocardiography of, atrial septal defects, 510–512
systemic-to-pulmonary artery shunts, 512
ventricular septal defects, 511–512
Sick sinus syndrome, in exercise testing, 249–250
Signal-averaged electrocardiography, for guiding of antiarrhythmia drug therapy, 70
for identification of high-risk survivors, 57–60
Single, biplane, multiplane, and three-dimensional transesophageal echocardiography, **361–386**
of aorta, 384–385
horizontal and vertical vectors of heart and, 363
instrumentation in, 362
multiplane examination, distal fundus views (deep transgastric), 373
gastroesophageal junction views, 373–374
lower and middle esophageal views, 374–379
proximal fundus views (transgastric), 370–373
upper esophageal views, 379–382
patient preparation and esophageal intubation, 362
of pulmonary veins, left pulmonary veins, 382–383
right pulmonary veins, 383–384
single and biplane examinations, distal fundus views (deep transgastric), 366
gastroesophageal junction views, 366–367
lower and middle esophageal views, 367–368
proximal fundus views (transgastric), 364–366
upper esophageal views, 368–370
three-dimensional, using TEE instrumentation, 385–386
transducer locations, imaging planes, and display, 362–364
Sinus tachycardia. See *Supraventricular tachycardia.*
Skin, appearance during maximal exercise testing, 216
preparation for electrocardiography, during exercise testing, 204–205
Smoking cessation, exercise effects, 344–345
psychobehavioral treatment for, 326–327
Sotalol, as cause of polymorphic ventricular tachycardias, 47
and preexcitation syndromes, 145
in ventricular tachycardias, 74, 77
Special populations and situations in exercise testing. See under *Exercise testing and cardiac rehabilitation.*
ST segment in exercise testing, 222–225. See also *Electrocardiography during exercise testing.*
depression, 223, 224, 230, 269, 282
elevation, 222–223
modifiers of ST-segment response, 224–225
normalization, 223
prognostic impact of ST changes, 223–224, 229
T wave changes, 224
U wave, 224
in women, 245, 247
Staphylococcal species, in endocarditis, 591
antibiotic therapy for, 596, 597
Staphylococcus aureus, in endocarditis, 590, 591
Static exercise. See *Arm-leg and static-dynamic exercise.*
Streptococcal species, in endocarditis, 590–591
antibiotic therapy for, 595–596
Streptococcus viridans, in endocarditis, 590–591
antibiotic therapy for, 595–596
Stroke, associated with patent foramen ovale, 575
Subaortic stenosis, 617–623
anatomy and physiology of, 617–619
clinical manifestations of, 619–620
hypertrophic obstructive cardiomyopathy in, 618–620, 622–623
laboratory findings in, 620–621
management of, 621–623
membranous, 619, 621–622
prevalence of, 617
tunnel, 618, 619, 622
Substance abuse, cardiovascular malformations and, 560–561
Sudden cardiac death, **1–9**. See also *Mortality rates.*
biologic model of, 2
from congenital heart disease, aortic valvular stenosis, 627–628
Eisenmenger's syndrome, 546
subaortic stenosis, 619–620, 622
tetralogy of Fallot, 646
transposition of great arteries, 658
definition of, 1
effect of implantable cardioverter-defibrillator, 97–98, 99–103
epidemiology of, 6–7
evaluation and management of survivors, **11–19**
complications of resuscitation, 11–12
diagnosis of arrhythmias, 14–17
diagnosis of heart disease, 12–14
electrophysiologic results of out-of-hospital cardiac arrest, 16
management, 17
functional modulation of structure, 2–3
identification of high-risk survivors, **55–63**
ambulatory monitoring, 56–57
combined noninvasive algorithm for predicting malignant arrhythmias, 60–61
heart rate variability, 60
signal-averaged electrocardiography, 57–60
incidence of, 1, 55
mechanisms involved in initiation of, 4–6
populations at risk for, 6–7
structural abnormalities and, 2
structural correlates and, 3–4
coronary arteries, 3–4
myocardium, 4
substrate trigger interaction, 1–6
Supravalvular aortic stenosis, 628–630
anatomy and physiology of, 629
clinical manifestations of, 629–630
laboratory findings in, 630
management of, 630
prevalence of, 628–629
Supraventricular tachycardia, **109–120**. See also *Atrioventricular nodal reentrant tachycardia.*
classification of, 109–114
atrial vs. junctional tachycardias, 110–114

based on first approximation to mechanism, 110–114
descriptive catalog, 110
historical approaches, 109–110
mechanistic classification, 110, 111
diagnosis and management of, 114–118
multifocal atrial tachycardia, 118
nonparoxysmal sinus tachycardia, 115
physiologic sinus tachycardia, 114
sinus node reentrant tachycardia, 114–115
unifocal (ectopic) atrial tachycardia, 115–118
Surgical ablation of ventricular tachycardias. See *Ablative therapy of ventricular tachycardias.*
Surgical risk evaluation with exercise testing, before cardiac surgery, 243
before noncardiac surgery, 236, 243
Survival of patients with congenital heart disease, **543–556**. See also *Sudden cardiac death.*
in aortic valve disease, 543
after cavopulmonary anastomoses, 554
Fontan operation, 554
Glenn operation, 554
in coarctation of aorta, 543–544, 632
in Eisenmenger's syndrome, 545–546
maternal mortality and, 703–705
natural survival patterns, 543–546
after operation or interventional catheterization, 546–554
for anomalies of great arteries, 549–550
for aortopulmonary shunts, 550–551
for coarctation of aorta, 634
for malformed valves, 546–548
for septal defects, 548–549, 604–605
for subaortic stenosis, 622
for tetralogy of Fallot, 552–554, 645
for transposition of great arteries, 551, 651–652, 654
tricuspid atresia with univentricular heart, 669–670
in patent ductus arteriosus, 545
in pulmonary valve stenosis, 544
in secundum atrial septal defects, 544–545
in tetralogy of Fallot, 545, 644
Syncope. See *Neurocardiogenic syncope.*
Systemic complications of congenital cyanotic heart disease. See *Complications of congenital cyanotic heart disease.*
Systemic emboli, arterial, cardiac and vascular causes of, 448
cerebrovascular ischemia and, 447
as complication of mitral valvuloplasty, 421
transesophageal echocardiography of, **447–458**
cardiac tumors and, 457–458
indications for, 449
sources of, aortic atheroma, 456–457
atrial septal aneurysm, 453, 454
cholesterol deposits, 464
in critical care patients, 499–500
left atrial spontaneous contrast and, 451–453
left atrial thrombus, 449–451
patent foramen ovale, 453–456
protruding atheromas, 464–465
transthoracic echocardiography of, 447–448
Systemic-to-pulmonary artery shunts, 512

Tachycardias. See also *Atrioventricular nodal reentrant tachycardia; Supraventricular tachycardia; Ventricular tachycardia.*
atrial, 251
ventricular, 251
Teratology of cardiovascular malformations, 557–562
atrioventricular valve development and, 559
early studies of, 558
embryologic mechanisms in, 558
environmental causes of, 557–558
fetal blood flow and, 559
future prospects and, 565
genetics and, 562–563
hallmarks of cardiovascular development and, 558
heritable coagulopathies and, 560
immune disorders and, 560
looping of tubular heart and, 558
maternal diabetes and, 560
mood-altering substances and, 560–561
neural crest cell migration and, 558–559
pathogenic classification of anomalies in, 559–560
phenylketonuria and, 560
population teratology and, 561–562
prevalence of congenital heart disease in live births, 559, 560
prevention of CHD and, 565
recurrence risks, 563–565
case-control studies of, 564
offspring risks, 563–564
sibling risks of CHD, 563
toxic environmental agents and, 561
Tetralogy of Fallot, **643–650**
clinical features of, 643–644
patient survival in, 545
postsurgical, 553–554
physical examination of, 644–645
pregnancy and, 703
with pulmonary atresia and ventricular septal defect, definition of, 644
physical examination of, 644
surgical therapy for, 647–649
right ventricular aneurysm in, 647
surgical therapy of, 645–646
in adults, 645
arrhythmias after, 646
long-term results of, 645–646
reoperation with, 646, 647
Thalidomide, teratology and, 557
Theophylline, and neurocardiogenic syncope, 187, 189, 190
Three-dimensional transesophageal echocardiography. See *Single, biplane, multiplane, and three-dimensional transesophageal echocardiography.*
Thrombolytic therapy, exercise testing after, 233, 234
exercise training after, 287, 293
Thrombus, left atrial, as source of systemic arterial emboli, 449–451
right atrial, transesophageal echocardiography of, 492–493
Torsades de pointes, in acquired long QT syndrome, 46, 47
drug therapy for, 68
drugs as cause of, 47, 74, 77
electrocardiographic example, 41
as form of ventricular tachycardias, 39–40
initiated by short-long cycle sequence, 56
Training of physicians for care of adult congenital heart disease, **717–720**
body of knowledge required for, 718–719
career decisions and, 720
existing medical disciplines and, 717–718
incorporation into existing pathways, 718
subspecialty certification and, 719
types of training experience required for, 719
Tranquilizers, as cause of arrhythmias, 283

Transcatheter closure techniques. See also *Catheter-based dilation techniques.*
choice of procedures, 585
for patent ductus arteriosus, 569–572
for patent foramen ovale, 575
postoperative residual defects from, 577
for secundum-type atrial septal defects, 572–575, 606
for vascular embolizations, 577–578
for ventricular septal defects, 575–577
Transesophageal echocardiography, in aortic dissection vs. degenerative disease, **461–471**
aortic insufficiency in, 469
classification of aortic dissection, 467
communicating and noncommunicating dissection in, 466–467
coronary artery involvement, 468–469
differential diagnosis of, 462–465
echocardiographic diagnosis of, 461–462
fluid extravasation in, 469–470
follow-up studies, 470–471
intimal tears in, 466
intramural hematoma and intramural hemorrhage in, 465–466
patient management, 470
side branch involvement, 467–468
true vs. false lumen, 465, 466
cardiac hemodynamics and, **475–485**
left ventricular diastolic function, 479–483
left ventricular systolic function, 475–479
potential applications of, 484–485
severity of mitral regurgitation, 483–484
during cardiopulmonary resuscitation, **529–535**
advantages of, 530–531
blood flow mechanisms in, 531
new CPR methods and, 531–533
rapid diagnosis in, 533–534
transthoracic echocardiography and, 529–530
in congenital heart disease of adults, **505–519**
atrioventricular junction examination, 516–518
complex segmental malformations, 514–516
conotruncal anatomy examination, 518
esophageal view, 505–510
specific malformations, 510–513
of coronary arteries, **521–526**
coronary artery anomalies, 523
coronary vascular reserve and, 523–526
transesophageal atrial pacing and, 526
transthoracic echocardiography vs., 521
in critical care patients, **489–501**
chest pain and complication of myocardial infarction, 493–495
complications of cardiac surgery, 495–497
dyspnea and pulmonary edema, 491, 493
endocarditis and embolic sources, 497–500
hypotensive patients, 490–491
miscellaneous indications, 500
studies at University of California at San Francisco, 489–490
technical considerations, 501
in endocarditis, **437–444**
cardiac imaging and, 437–438
clinical implications of, 444
future developments and, 443–444
transthoracic echocardiography vs., 438
indications and technical considerations in, **355–359**
antibiotic prophylaxis, 358
complications, 358–359
equipment and location, 356–357
indications and contraindications, 355–356
personnel, 356
procedural guidelines, 357–358
intraoperative assessment of left ventricular function, **389–396**
global left ventricular function, 389–393
regional ischemia, 393–396
mitral regurgitation evaluation, **399–407**
color flow detection and, 399–402
pulsed and continuous wave Doppler findings, 402–407
mitral valvuloplasty guided by, **409–423**
balloon positioning and dilatation, 416–417
early detection of complications, 419–423
immediate assessment of results, 417–418
methodology, 409–410
patient selection, 410–414
transeptal puncture and, 414–416
prosthetic valve evaluation by, **427–435**
aortic valve prosthesis, 433–435
approach to assessment, 428
mitral valve prosthesis, 428–433
tricuspid valve prosthesis, 435
single, biplane, multiplane, and three-dimensional, **361–386**
of aorta, 384–385
instrumentation, 362
multiplane examination, 370–382
patient preparation and intubation, 362
of pulmonary veins, 382–384
single and biplane examinations, 364–370
three-dimensional using TEE instrumentation, 385–386
transducer locations, imaging planes, and display, 362–364
in systemic arterial emboli, **447–458**
cardiac tumors and, 457–458
cerebrovascular ischemia and, 447–448
sources of emboli, 449–457
Transesophageal probes. See also *Single, biplane, multiplane, and three-dimensional transesophageal echocardiography.*
cleansing and storage of, 357
insertion of, 358
types of, 356–357, 362
Transposition of great arteries, **651–664**
in adults, 651–652
congenitally corrected, 659–663
anomalies associated with, 659
clinical and anatomic implications of, 659–660
definition of, 659
diagnostic considerations in, 660
electrophysiologic considerations in, 662
functional capacity and ventricular function in, 660–662
surgical considerations in, 660
definition of, 651
diagnostic considerations, 652–653
electrophysiologic considerations, 657–659
epidemiology of, 651
functional capacity and ventricular function in, 656–657
pregnancy and, 704–705
surgical considerations, 653–655
morbidity following, 654–656
mortality following, 654
patient survival, 551, 651–652, 654
reoperation following Mustard's operation, 655
transposition complex, definition of, 651
Transthoracic echocardiography, of arterial systemic emboli, 447–448
in cardiopulmonary resuscitation, 529–530

of coronary arteries, **521–526**
in critical care patients, 499
in endocarditis, 438
of prosthetic valves, 429, 431
Treadmill, advantages of, 202–203
calculating oxygen uptake, 203
ergometer exercise testing vs., 260–261
Tricuspid atresia with univentricular heart, Fontan procedure for, **665–671**
anatomy of tricuspid atresia, 665–669
arrhythmias following, 670–671
development of surgical procedure for, 667–669
exercise capacity following, 670
protein-losing enteropathy following, 671
reoperation for, 670
survival following, 669–670
pregnancy and, 705
Tricuspid valve, Ebstein's anomaly of, survival after surgical procedure for, 548
prosthesis for, transesophageal echocardiography of, 435
Tumors, cardiac, in systemic arterial emboli, 457–458
Tunnel subaortic stenosis, 618, 619, 622
Turner syndrome, male, 613
XO, 631
Type A behavior modification, 324–326

Ullrich syndrome, 613
Unifocal (ectopic) atrial tachycardia, 115–118
Univentricular heart. See *Tricuspid atresia with univentricular heart.*
Urate metabolism, in congenital cyanotic heart disease, 695–696

Valve prostheses. See *Prosthetic valves.*
Valvular stenoses. See *Aortic valvular stenosis; Mitral valve stenosis; Pulmonary valvular stenosis; Subaortic stenosis.*
Vancomycin, for endocarditis, 596, 597, 600
Vascular embolizations, transcatheter closure techniques, 577–578
Vasodilators, effect on exercise testing, 245
Ventilatory gas exchange analysis, 207–211
calculations for basic gas exchange data, 211
clinical applications, 207
hand signals for expressing pain, 210
measurement of oxygen uptake, 208–210
methodological considerations, 210–211
predicting oxygen uptake, 207–208
Ventricular premature depolarizations (VPDs), combined with other noninvasive diagnostic methods, 60
in patients with ventricular tachycardias, 74, 77
prognostic of sudden cardiac death, 57
Ventricular septal defect, 606–609
anatomy and physiology of, 606
clinical presentation of, 606–607
endocarditis and, 598–599
incidence of, 606
medical and surgical management of, 607–609
patient survival in, postsurgical, 549
pregnancy and, 706
transcatheter closure techniques, 575–577
transesophageal echocardiography of, 511–512
Ventricular tachycardia. See also *Ablative therapy of ventricular tachycardias.*
diagnosis of, ambulatory monitoring, 56–57
combined noninvasive algorithm, 60–61
heart rate variability, 60
signal-averaged electrocardiography, 57–60
in exercise testing, 251, 282
lethal or potentially lethal, 65
monomorphic, **21–37**
ablative therapy of, 27–32
mechanisms of, 21–22
natural history of, 22–25
nonsustained ventricular tachycardias, 24–25
pacemakers and cardioverter-defibrillators for, 32–33
pharmacologic therapy of, 25–27
polymorphic ventricular tachycardias vs., 39
substrates of, 22
sustained ventricular tachycardias, 22–24
therapy of, 25–33
pharmacologic therapy of, **65–83**
methods for guiding therapy, 69–72
overview of anti-arrhythmic agents, 66–67
principles of successful management, 67–69
summary of drug use, 78
with previous lethal or potentially lethal tachycardias, 75–77
without previous lethal or potentially lethal tachycardias, 72–74
polymorphic, **39–54**
acquired long QT syndrome, 46–50, 52
clinical presentation of, 46–47
mechanism of, 47–49
therapy of, 49–50
coronary revascularization for, 90–91
definitions, 39–40
idiopathic long QT syndrome, 40–46, 52
clinical presentation of, 41–42
diagnosis of, 42–43
mechanisms of, 43–45
treatment of, 45–46
ischemic heart disease and, 50–52
monomorphic ventricular tachycardias vs., 39
in normal hearts, 52
pathogenesis of, 52
torsades de pointes, 39–40
with ventricular fibrillation, degeneration of atrial fibrillation to ventricular fibrillation, 141–142
as mechanism of sudden cardiac death, 55
premature ventricular contractions (PVCs) and, 1
and sudden cardiac death, 2
Verapamil, in atrioventricular nodal reentrant tachycardia, 168
degeneration of atrial fibrillation to ventricular fibrillation and, 142
induction of atrial tachycardia and, 112
preexication syndromes and, 133, 144
Views in transesophageal echocardiography. See *Single, biplane, multiplane, and three-dimensional transesophageal echocardiography.*
VPDs. See *Ventricular premature depolarizations (VPDs).*

Weight training for cardiac rehabilitation, 262–263, 298
Wolff-Parkinson-White syndrome, antidromic AV reentrant tachycardia and, 138
atrial fibrillation and, 139
in exercise testing, 248
sudden death as first manifestation of, 142
Women, interpretation of exercise tests for, 245, 247

Women *(Continued)*
ST segment depression in, 224
Worksite-based exercise training. See *Home-based and worksite-based exercise training.*

YAG (neodymium:yttrium-aluminum-garnet) laser photocoagulation, for ablation of ventricular tachycardias, 93